<noframes id="zd9f3">

    <address id="zd9f3"></address>

    <address id="zd9f3"></address>
    <address id="zd9f3"></address>

    <address id="zd9f3"><nobr id="zd9f3"><meter id="zd9f3"></meter></nobr></address>
    1. GPCR/G Protein
    2. Adrenergic Receptor

    Adrenergic Receptor

    Adrenergic receptors are a class of G protein-coupled receptors that are targets of the catecholamines, especially norepinephrine and epinephrine. Many cells possess these receptors, and the binding of a catecholamine to the receptor will generally stimulate the sympathetic nervous system. The sympathetic nervous system is responsible for the fight-or-flight response, which includes widening the pupils of the eye, mobilizing energy, and diverting blood flow from non-essential organs to skeletal muscle. There are two main groups of adrenergic receptors, α and β, with several subtypes. α receptors have the subtypes α1 and α2. β receptors have the subtypes β1, β2 and β3. All three are linked to Gs proteins, which in turn are linked to adenylate cyclase. Agonist binding thus causes a rise in the intracellular concentration of the second messenger cAMP. Downstream effectors of cAMP include cAMP-dependent protein kinase (PKA), which mediates some of the intracellular events following hormone binding.

    Adrenergic Receptor 相关产品 (183):

    Cat. No. Product Name Effect Purity
    • HY-B0468
      Isoprenaline hydrochloride Agonist >99.0%
      Isoprenaline hydrochloride是一种非选择性的β-肾上腺素能受体激动剂,具有有效的外周血管扩张剂,支气管扩张剂和心脏刺激活性。
    • HY-13715B
      Norepinephrine bitartrate monohydrate Agonist 99.75%
      Norepinephrine bitartrate monohydrate 是β1-选择性的肾上腺素能受体激动剂,EC50 为 5.37 μM。
    • HY-B0573
      Propranolol hydrochloride Antagonist 99.92%
      Propranolol hydrochloride是一种非选择性β-肾上腺素能受体(βAR)拮抗剂, IC50 值为12 nM。
    • HY-13951
      ICI 118,551 hydrochloride Antagonist 98.50%
      ICI 118,551 hydrochloride 是一种高度选择性的 β2肾上腺素能受体 拮抗剂,结合β2,β1 和 β3肾上腺素能受体的Ki 值分别为 0.7,49.5 和 611 nM。
    • HY-B0471
      (R)-(-)-Phenylephrine hydrochloride Agonist 98.10%
      (R)-(-)-Phenylephrine hydrochloride是一种选择性的α1-肾上腺素能受体激动剂,对α1D,α1B 和α1A 受体的pKis 分为5.86,4.87和4.70。
    • HY-B1298
      Methoxamine hydrochloride Agonist
      Methoxamine hydrochloride 是去甲肾上腺素能受体α1 的激动剂。
    • HY-19436
      Solabegron Agonist
      Solabegron (GW 427353) 是 β3 肾上腺素能受体 (β3-AR) 的选择性激动剂, 在中国仓鼠卵巢细胞中测得的 EC50 值为22 nM。目前正在被用于开发治疗膀胱过度活跃和肠易激综合征。
    • HY-N0761
      3-Hydroxy-4-methoxycinnamic acid Inhibitor
      3-Hydroxy-4-methoxycinnamic acid (Isoferulic acid) 是具有抗糖尿病活性的肉桂酸衍生物。3-Hydroxy-4-methoxycinnamic acid 结合并激活 α1-肾上腺素能受体 (IC50=1.4 μM),增强 β-内啡肽的分泌 (EC50=52.2 nM) 并增加体外葡萄糖的使用。
    • HY-14773
      Mirabegron Agonist 99.08%
      Mirabegron 是一种选择性的肾上腺素受体 (β3-adrenoceptor) 激动剂,EC50 为 22.4 nM。
    • HY-N0127
      Yohimbine Hydrochloride Antagonist 99.85%
      Yohimbine hydrochloride 是α-2肾上腺素能受体抑制剂,阻断突触前或突触后的α-2肾上腺素能受体,引起去甲肾上腺素和多巴胺的释放。
    • HY-B0447B
      L-Epinephrine Agonist >99.0%
    • HY-B0162A
      Ivabradine hydrochloride Inhibitor 98.39%
      Ivabradine是可口服的,超极化激活的环核苷酸门控离子通道 (HCN) 通道阻滞剂。
    • HY-B1614
      Clenbuterol hydrochloride Agonist 99.23%
      Clenbuterol hydrochloride (NAB-365 hydrochloride) 是 β2 adrenergic受体激动剂。它是一种强效的支气管扩张剂,具有脂肪燃烧性能。
    • HY-B0193A
      Prazosin hydrochloride Antagonist 99.73%
    • HY-B0006
      Carvedilol Inhibitor 99.93%
      Carvedilol(BM14190)是非选择性β和α1阻断剂,能抑制LDL的氧化,IC50为3.8 μM。
    • HY-12987
      Pimozide Antagonist 99.88%
      Pimozide 是 dopamine receptor 的拮抗剂,对 dopamine D2,D3 和 D1 受体的 Ki 值分别为 1.4 nM,2.5 nM 和 588 nM,同时对 α1-adrenoceptor 也有较高亲和性,Ki 值为 39 nM;Pimozide 也是 STAT3STAT5 的抑制剂。
    • HY-B0437
      Sotalol hydrochloride Antagonist 99.77%
    • HY-17498
      Atenolol Antagonist >98.0%
    • HY-B0362A
      Phentolamine mesylate Antagonist 99.83%
      Phentolamine mesylate是竞争性,可逆的 α-肾上腺素能受体 拮抗剂,IC50 在5和30 nM之间。
    • HY-B0443A
      Xylazine hydrochloride Agonist 99.90%
    Isoform Specific Products

    Your Search Returned No Results.

    Sorry. There is currently no product that acts on isoform together.

    Please try each isoform separately.